Illinois State Dental Society Endorses iCoreConnect's Popular Cloud ePrescribing Software, iCoreRx
iCoreConnect, Inc. (NASDAQ: ICCT) announced the endorsement of its cloud ePrescribing software, iCoreRx, by the Illinois State Dental Society. This marks the 23rd state dental or medical association to specifically endorse iCoreRx. The endorsement is significant as it streamlines prescription writing for dentists and medical professionals, ensuring quick, accurate, and compliant steps. The endorsement also aligns with the upcoming ePrescribing law in Illinois, making iCoreRx a seamless and affordable solution for controlled substance prescribers in the state.
11/16/2023 - 08:30 AM
OCOEE, FL, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – iCoreConnect, Inc. (NASDAQ: ICCT)(“iCore” or the “Company”) a cloud-based software and technology company focused on increasing workflow productivity and customer profitability through its enterprise and healthcare workflow platform, today announced the endorsement of its cloud ePrescribing software, iCoreRx, by the Illinois State Dental Society (“ISDS”) .
With this ISDS endorsement, more than 60% of state dental and medical associations in the U.S. now endorse iCoreConnect products. It is the 23rd state dental or medical association to specifically endorse iCoreRx cloud ePrescribing, which streamlines everything a doctor needs to prescribe quickly, accurately, and securely.
Robert McDermott, President and CEO of iCoreConnect, stated, “Illinois is a new state endorsement for us. We’re thrilled to partner with such a great state organization. The Illinois State Dental Society works diligently to bring its members quality options that will help them work more effectively and produce greater business results. We're eager for their member dentists to experience a better way of prescription writing that takes just a few fast, accurate, and compliant steps.”
As of January 1, 2024, all Illinois controlled substance prescribers, including dentists, who prescribe more than 150 schedule II-V controlled substances in a calendar year need to prescribe electronically. Christopher Larsen, DDS, ISDS Member Services Committee Chair, commented, “ISDS is excited to partner with iCoreConnect to offer our Membership a seamless and affordable solution to meet the requirements of the upcoming ePrescribing law through iCoreRx. All endorsed partners are rigorously vetted by the ISDS Member Services Committee. iCoreRx stood out from competitors due to its ability to integrate with almost any practice management software and ease of use, all at an affordable price.”
About iCoreConnect, Inc. (NASDAQ: ICCT)
iCoreConnect, Inc. is a market leading, cloud-based software and technology company focused on increasing workflow productivity and practice profitability through its enterprise and healthcare workflow platform of applications and services. iCoreConnect is most notably known for its innovation in solving healthcare business problems. iCoreConnect’s philosophy places a high value on customer feedback, allowing iCoreConnect to respond to the market’s needs. iCoreConnect touts a platform of 16 SaaS enterprise solutions and more than 100 product endorsements with state or regional healthcare associations across the United States.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the Company’s revenue and annualized recurring revenue estimates for 2023, the Company’s ability to grow opportunities within ePrescription and insurance verification, and the Company's ability to continue to expand its reach into medical customers. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. The Company has attempted to identify forward-looking statements by terminology including ‘believes,’ ‘estimates,’ ‘anticipates,’ ‘expects,’ ‘plans,’ ‘projects,’ ‘intends,’ ‘potential,’ ‘may,’ ‘could,’ ‘might,’ ‘will,’ ‘should,’ ‘approximately’ or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. “Risk Factors” in the Company’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. The Company undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Investor Contacts:
What is iCoreConnect, Inc. (NASDAQ: ICCT) announcing?
iCoreConnect announced the endorsement of its cloud ePrescribing software, iCoreRx, by the Illinois State Dental Society.
Why is the ISDS endorsement significant?
The ISDS endorsement streamlines prescription writing for dentists and medical professionals, ensuring quick, accurate, and compliant steps. It also aligns with the upcoming ePrescribing law in Illinois, making iCoreRx a seamless and affordable solution for controlled substance prescribers in the state.
How many state dental or medical associations have endorsed iCoreRx?
More than 60% of state dental and medical associations in the U.S. now endorse iCoreConnect products, with the ISDS being the 23rd to specifically endorse iCoreRx.
What is the impact of the endorsement on iCoreRx?
The endorsement solidifies iCoreRx's position as a leading cloud ePrescribing software, expanding its reach and credibility in the healthcare industry.
